Dose-response relationship of sublingual nitroglycerin with brachial artery dilatation and change in central and peripheral augmentation index

Oliver, James; Bowler, A. J.; Beudeker, Querine; Cate, Thomas ten; Webb, David J.

doi:10.1016/j.clpt.2005.01.013

Cited by 9 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the effect of NTG on these parameters is well known. Oliver et al conducted a study in which they established the dose-relationship of sublingual NTG to changes in BAD and radial and aortic AIx in healthy men [28].The change in heart rate, brachial diastolic blood pressure, aortic and radial AIx and BAD following 0.4 mg of NTG in our study are largely in agreement with their data.…”

Section: Discussionsupporting

confidence: 81%

“…This PWF information has become a powerful tool to investigate the cardiovascular response in vivo in humans to disease states and drugs. It was notably shown more reliable in detecting arterial triptan and nitrate-induced vascular effects than the classically used brachial artery diastolic (DBP) and systolic blood pressure (SBP) [25][26][27][28]. High resolution ultrasound allows the real time measurement of changes in the brachial artery diameter (BAD) induced by vasoactive drugs, notably triptans and nitrates [25].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The potent calcitonin gene‐related peptide receptor antagonist, telcagepant, does not affect nitroglycerin‐induced vasodilation in healthy men

Schueren

Blanchard²,

Murphy³

et al. 2011

Brit J Clinical Pharma

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT WHAT THIS STUDY ADDS• This study shows that telcagepant, at a supra-therapeutic dose for the treatment of acute migraine headache, has no clinically relevant effect on NTG-induced haemodynamic changes in healthy male volunteers. There is also no measurable vasoconstrictor effect of telcagepant as such in both the central and peripheral vascular bed. The results of the present study support the favourable cardiovascular safety profile of telcagepant and indicate that CGRP is not involved in NTG-induced vasodilation in humans. AIMSTo assess the effect of the calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (NTG). METHODSTwenty-two healthy male volunteers participated in a randomized, placebo-controlled, double-blind, two-period, crossover study. Subjects received 500 mg telcagepant or placebo followed, 1.5 h later, by 0.4 mg NTG. To assess the haemodynamic response the following vascular parameters were measured: blood pressure, aortic augmentation index (AIx) and brachial artery diameter (BAD). Data are presented as mean (95% confidence interval, CI). RESULTSThe aortic AIx following NTG decreased by -18.50 (-21.02, -15.98) % after telcagepant vs. -17.28 (-19.80, -14.76) % after placebo. The BAD fold increase following NTG was 1.14 (1.12, 1.17) after telcagepant vs. 1.13 (1.10, 1.15) after placebo. For both AIx and BAD, the hypothesis that telcagepant does not significantly affect the changes induced by NTG is supported (P < 0.0001). In addition, no vasoconstrictor effect of telcagepant could be demonstrated. CONCLUSIONSTelcagepant did not affect NTG-induced haemodynamic changes. These data suggest that NTG-induced vasodilation is not CGRP dependent.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

The potent calcitonin gene‐related peptide receptor antagonist, telcagepant, does not affect nitroglycerin‐induced vasodilation in healthy men

Schueren

Blanchard²,

Murphy³

et al. 2011

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…FMD was quantified as a percentage change from baseline in brachial artery diameter after 5 min of forearm ischemia. Endothelium-independent vasomotor function was assessed using 25 μg nitroglycerine (NTG) by sublingual administration (25). …”

Section: Methodsmentioning

confidence: 99%

Risk Factors for Metabolic Syndrome Independently Predict Arterial Stiffness and Endothelial Dysfunction in Patients With Chronic Kidney Disease and Minimal Comorbidity

Lilitkarntakul

Dhaun²,

Melville³

et al. 2012

Diabetes Care

View full text Add to dashboard Cite

OBJECTIVEMetabolic syndrome (MS) is common in patients with chronic kidney disease (CKD), but its contribution to arterial stiffness and endothelial dysfunction in CKD is not well defined. We hypothesized that risk factors for MS would independently predict arterial stiffness and endothelial dysfunction in CKD patients.RESEARCH DESIGN AND METHODSRisk factors for MS, carotid-femoral pulse wave velocity (CF-PWV) and flow-mediated dilation (FMD) as measures of arterial stiffness and endothelial dysfunction, respectively, were assessed in 113 minimally comorbid CKD patients and in 23 matched control subjects.RESULTSCF-PWV correlated with systolic blood pressure (SBP), waist circumference, and plasma glucose (r2 = 0.25, 0.09, and 0.09; P < 0.01 for all). FMD correlated with SBP (r2 = 0.09; P < 0.01) and waist circumference (r2 = 0.03; P < 0.05). CF-PWV increased progressively (r2 = 0.07; P < 0.01) with increasing number of risk factors for MS. In multiple linear regression, SBP and waist circumference were independent determinants of CF-PWV, whereas only SBP predicted FMD.CONCLUSIONSThe number of MS risk factors is an important determinant of arterial stiffness in CKD patients irrespective of the degree of renal impairment. Although BP remains the major determinant of arterial stiffness and endothelial dysfunction, waist circumference independently predicts arterial stiffness. MS risk factors, particularly abdominal girth, are potential targets for future interventional studies in patients with CKD.

show abstract

“…Furthermore, the IC GTN dose administered in our study (100 µg) is lower when compared with others 5. Data from peripheral23 and coronary24 dose–response experiments suggest that the lower GTN dose better reflects the half maximal effective concentration (EC 50 ) of the drug, hence we felt the current dose is better equipped to interrogate human coronary endothelial-independent function and may partly explain the positive signal in this study.…”

Section: Discussionmentioning

confidence: 57%

Evaluation of human coronary vasodilator function predicts future coronary atheroma progression

Sidharta

Baillie

Howell

et al. 2018

Heart

View full text Add to dashboard Cite

show abstract

Dose-response relationship of sublingual nitroglycerin with brachial artery dilatation and change in central and peripheral augmentation index

Cited by 9 publications

References 4 publications

The potent calcitonin gene‐related peptide receptor antagonist, telcagepant, does not affect nitroglycerin‐induced vasodilation in healthy men

The potent calcitonin gene‐related peptide receptor antagonist, telcagepant, does not affect nitroglycerin‐induced vasodilation in healthy men

Risk Factors for Metabolic Syndrome Independently Predict Arterial Stiffness and Endothelial Dysfunction in Patients With Chronic Kidney Disease and Minimal Comorbidity

Evaluation of human coronary vasodilator function predicts future coronary atheroma progression

Contact Info

Product

Resources

About